Genmab — Maj 2018

[Mayflower]

Noget positivt om TV eller ofa vil være rigtig godt. No one likes a one-trick pony.

[Sukkeralf]

[Plimsoller]

Alcyone er primært for EU såvidt jeg kan forstå, men hvad er så primært for USA, og hvor er vi med det?

[Sukkeralf]

Dara-Rev-Dex - fase III kommer i sensommeren, så filing omkring årsskiftet og godkendelse sommer 2019

[E_L]

@Sukkeralf I cant figure out what drug Spicer is talking about; is it HuMax-AXL-ADC?

[E_L]

coincidentally this HuMax-AXL-ADC Safety Study in Patients With Solid Tumors is now looking to recruit almost 300 patients, alsmost 2x what they said first https://clinicaltrials.gov/ct2/history/NCT02988817?A=5&B=6&C=merged

[E_L]

also: "The Expansion part of the trial has been initiated " ; i read that as :
they started phase 2 ?

[Sukkeralf]

I think he mentioned AXL molecules (probably Bemcentinib) in combination with Pemblizumab (Keytruda) and Erlotinib (Tarceva). BergenBio´s Bemcentinib is in clinical studies with both.

[Sukkeralf]

Just a link to show that AXL becomes more and more intresting

[E_L]

ok thx

[Joakim_Von_And]

Dejligt at se kursen kryber op ad under lille omsætning,, det kunne godt blive ved nogle dage tror jeg..

[Sukkeralf]

And thanks for AXL ADC link - I think that is very positive for Genmab

[E_L]

yes, i agree. the rationale to enlarge the trial could be as simple as 'it is cheaper for us due to the cost split with Seatlle Genetics', but my guess is that they are expanding to other cancers... Really exciting

[Sukkeralf]

They dont have cost split with AXL - here it a regular licens deal - milestones and royalty to SA

[Sukkeralf]

SG'

[Sukkeralf]

It must be because safety looks fine and maybe they have allready seen some efficacy and wants to be aggressive

[Her_for_at_lære]

Dejligt at se kursen går op. Hvad er det der driver den frem? Forventninger til Q1 den 8. Maj?

[E_L]

oh, i got that wrong then, indeed, the agreements with SG differ per product

[nohope]

• 30 point. What´s up, Doc ?

[Bulder]

Tx E L. Good progress in the axl-study. It looks like they have already found the optimal dose in the 3 weeks arm. So one of the arms has entered phase 2a.